Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.ijid.2021.02.041 http://scihub22266oqcxt.onion/10.1016/j.ijid.2021.02.041 33592340!7881693!33592340     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Infect+Dis 2021 ; 105 (ä): 319-325 Nephropedia Template TP {{tp|p=33592340|t=2021. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study |pdf=|usr=}}{{33592340}} gab.com Text Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study JO: Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33592340 #FOAvip OBJECTIVES: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients with tocilizumab-refractory COVID-19 disease. METHODS: A prospective cohort of patients with COVID-19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) with selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline, and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a 6-point ordinal scale, from baseline to day 21. RESULTS: The study included 20 cases and 20 controls (mean age 65.3 +/- 12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. The in-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P = 0.527). CONCLUSIONS: Treatment with anakinra was not useful in improving the prognosis of patients with tocilizumab-refractory severe COVID-19. Twit Text FOAVip Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study ????Int J Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=33592340 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33592340 #FOAvip English Wikipedia <ref>{{Cite pmid|33592340}}</ref> Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study #MMPMID33592340 de la Calle C; Lopez-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sanchez-Fernandez M; Fernandez-Ruiz M; Perez-Jacoiste Asin MA; Caro-Teller JM; Garcia-Garcia R; Catalan M; Martinez-Lopez J; Sevillano A; Origuen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gomez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM Int J Infect Dis 2021[Apr]; 105 (ä): 319-325 PMID33592340show ga OBJECTIVES: A subgroup of patients with SARS-CoV-2 infection was thought to have developed cytokine release syndrome and were treated with tocilizumab; however, a significant percentage of patients evolved. This study aimed to determine the usefulness of anakinra as a rescue treatment for patients with tocilizumab-refractory COVID-19 disease. METHODS: A prospective cohort of patients with COVID-19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) with selected controls in a historical cohort of patients treated with tocilizumab. Cases and controls were matched by age, comorbidities, pulse oximetry oxygen saturation to fraction of inspired oxygen (SpO2/FiO2) ratio at baseline, and time elapsed since the initiation of treatment with tocilizumab. The primary outcome was the improvement in clinical status measured by a 6-point ordinal scale, from baseline to day 21. RESULTS: The study included 20 cases and 20 controls (mean age 65.3 +/- 12.8 years, 65% males). No differences were found in the clinical improvement rates at 7, 14 and 21 days of follow-up. The in-hospital mortality rate for patients receiving anakinra was 55% vs. 45% in the control group (P = 0.527). CONCLUSIONS: Treatment with anakinra was not useful in improving the prognosis of patients with tocilizumab-refractory severe COVID-19. |*COVID-19 Drug Treatment[MESH] |*SARS-CoV-2[MESH] |Aged[MESH] |Antibodies, Monoclonal, Humanized/*therapeutic use[MESH] |COVID-19/complications[MESH] |Case-Control Studies[MESH] |Cohort Studies[MESH] |Cytokine Release Syndrome/*drug therapy/etiology[MESH] |Female[MESH] |Hospital Mortality[MESH] |Humans[MESH] |Immunomodulation/drug effects[MESH] |Interleukin 1 Receptor Antagonist Protein/*therapeutic use[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |Salvage Therapy[MESH] |Spain/epidemiology[MESH] |Treatment Failure[MESH]Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: (epmc).pdf DeepDyve Pubget Overpricing